Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Department of Oncology, The People's Hospital of Guizhou Province, Guiyang 550001, China.
Future Oncol. 2022 Feb;18(6):727-738. doi: 10.2217/fon-2021-1071. Epub 2021 Dec 9.
Pulmonary sarcomatoid carcinoma (PSC) is a pathological subtype of non-small-cell lung cancer. Although the incidence of PSC in lung cancer is very low, it is an aggressive cancer, leading to a poor prognosis. Currently, there is no standard treatment for advanced PSC. Targeted therapy can be used for patients with mutations and patients with other driver gene mutations may also benefit from treatment. The emergence of immune checkpoint inhibitors also provides potential options for advanced PSC treatment, but more clinical data is needed. Additionally, more research may be warranted to explore the effects of chemotherapy, radiotherapy and antiangiogenic therapy. In this review, the authors summarize the research regarding the treatment of advanced PSC.
肺肉瘤样癌（PSC）是一种非小细胞肺癌的病理亚型。虽然 PSC 在肺癌中的发病率非常低，但它是一种侵袭性癌症，导致预后不良。目前，晚期 PSC 没有标准的治疗方法。对于有 突变的患者可以使用靶向治疗，而其他驱动基因突变的患者也可能从治疗中获益。免疫检查点抑制剂的出现也为晚期 PSC 的治疗提供了潜在的选择，但需要更多的临床数据。此外，可能需要更多的研究来探索化疗、放疗和抗血管生成治疗的效果。在这篇综述中，作者总结了关于晚期 PSC 治疗的研究。
